Guidance Capital Inc. Takes Position in Alkermes plc (NASDAQ:ALKS)

Guidance Capital Inc. bought a new stake in Alkermes plc (NASDAQ:ALKS) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 15,826 shares of the company’s stock, valued at approximately $428,000.

Several other institutional investors also recently added to or reduced their stakes in the company. Alps Advisors Inc. boosted its holdings in shares of Alkermes by 0.4% in the third quarter. Alps Advisors Inc. now owns 122,916 shares of the company’s stock valued at $3,443,000 after acquiring an additional 529 shares during the period. Fisher Asset Management LLC grew its position in Alkermes by 1.0% during the 4th quarter. Fisher Asset Management LLC now owns 59,942 shares of the company’s stock worth $1,663,000 after purchasing an additional 572 shares during the last quarter. Victory Capital Management Inc. increased its stake in Alkermes by 0.9% in the fourth quarter. Victory Capital Management Inc. now owns 76,718 shares of the company’s stock valued at $2,128,000 after purchasing an additional 675 shares during the period. CWM LLC raised its holdings in shares of Alkermes by 36.7% in the first quarter. CWM LLC now owns 2,732 shares of the company’s stock valued at $74,000 after buying an additional 733 shares during the last quarter. Finally, McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Alkermes during the fourth quarter worth about $30,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Price Performance

Shares of NASDAQ ALKS traded down $0.19 during midday trading on Friday, hitting $24.10. The company had a trading volume of 3,405,843 shares, compared to its average volume of 2,020,961. The firm has a market capitalization of $4.08 billion, a price-to-earnings ratio of 9.53, a price-to-earnings-growth ratio of 0.49 and a beta of 0.47. Alkermes plc has a twelve month low of $22.01 and a twelve month high of $32.89. The business has a 50-day simple moving average of $24.28 and a two-hundred day simple moving average of $26.57. The company has a quick ratio of 2.77, a current ratio of 3.20 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.15). The company had revenue of $350.37 million for the quarter, compared to analyst estimates of $360.26 million. Alkermes had a net margin of 25.17% and a return on equity of 20.31%. Alkermes’s revenue was up 21.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.10) earnings per share. Equities research analysts anticipate that Alkermes plc will post 2.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Jefferies Financial Group upped their price objective on Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, April 9th. TD Cowen assumed coverage on Alkermes in a report on Monday, June 17th. They set a “buy” rating and a $34.00 price target for the company. StockNews.com lowered shares of Alkermes from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Piper Sandler restated an “overweight” rating and set a $39.00 price objective on shares of Alkermes in a research report on Monday, April 1st. Finally, Robert W. Baird began coverage on shares of Alkermes in a report on Tuesday, March 19th. They issued an “outperform” rating and a $37.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $36.50.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.